Brief summary

To demonstrate that the BioFreedomTM Drug Coated Stent is non-inferior to the Gazelle™ BMS arm of the Leaders Free study in high bleeding risk patients treated with one month DAPT only

Primary endpoints

  • Safety:

The composite of cardiac death and myocardial infarction at 1 year

  • Efficacy:

The incidence of clinically driven target lesion revascularization at 1 year

CERC Services

  •  CEC
  • Monitoring
  • Core Laboratory
  • Regulatory


85 sites in total distributed throughout Europe and North America (US and Canada). CERC is responsible for the European sites. These are distributed by 5 countries: France, Denmark, Germany, UK and Italy.

Centers number

16 centers managed by CERC.

Latest News

EuroPCR 2017: Two-year follow-up of LEADERS FREE ACS: is there a place left for BMS in ACS?